Pediatrics Department, Peking University Shenzhen Hospital, Shenzhen, China.
Shantou University Medical College, Shantou, China.
J Matern Fetal Neonatal Med. 2023 Dec;36(2):2280527. doi: 10.1080/14767058.2023.2280527. Epub 2023 Nov 15.
Comparing with other diseases, early onset sepsis (EOS) is a global health concern in neonatal period for its high morbidity and mortality rates. In recent years, many studies have contributed to the figure out the expression patterns of circulating micro-RNAs (miRNAs) in different diseases and progressions, which could function as diagnostic biomarkers for EOS. The purpose of this study was to analyze the expression patterns of selected miRNAs and evaluate their diagnostic value for early detection and treatment.
This was a prospective cross-sectional study conducted from 1 July 2021 to 30 June 2022. We collected surplus peripheral blood and demographic statistics of septic neonates and non-infected neonates during the first 24 h after delivery and obtained 11 candidate miRNAs by literature screening. First, we extracted the candidate miRNAs from the serum of selected neonates and analyzed their expression levels, and then the receiver operating characteristic (ROC) curve was used to select the differentially expressed miRNAs. We analyzed their sensitivity and specificity and obtained the best diagnostic panel. Finally, with the help of differentially expressed miRNAs, we performed gene ontology (GO) enrichment and protein-protein interaction (PPI) analyses by their target genes.
In patients with EOS, three miRNAs (mir-223-3p, mir-15a-5p, and mir-17-5p) in serum were significantly downregulated, and mir-146a-5p, mir-1-3p, and mir-16-5p were upregulated. The diagnostic value of these miRNAs (miR-15a-5p, AUC = 0.67; miR-223-3p, AUC = 0.72; miR-16-5p, AUC = 0.68; miR-17-5p, AUC = 0.70; miR-1-3p, AUC = 0.69; miR-146a-5p, AUC = 0.72) was moderate, and the diagnostic panel constructed by miR-15a-5p, miR-223-3p, and miR-16-5p possessed a comparatively higher diagnostic value (AUC = 0.85, sensitivity: 74.6%, specificity: 86%), indicating that their combined application may be a promising biomarker for clinical diagnosis of EOS. According to GO enrichment analysis, most proteins encoded by target genes were located in the cytosol as for cellular component (CC), for molecular function (MF), most proteins acted as regulators in protein binding, and for biological process (BP). Most genes function in positive or negative regulation of transcription from RNA polymerase II promoter, and the top 10 hub genes were CDKN1A, YAP1, CCNE1, CCND1, CKK6, ERBB4, CHEK1, DICER1, VEGFA, and APP by rank degree after PPI construction.
The three-miRNA panels (miR-15a-5p, miR-223-3p, and miR-16-5p) may be a novel noninvasive biological marker for EOS screening.
与其他疾病相比,早发性败血症(EOS)在新生儿期因其高发病率和死亡率而成为全球健康关注的焦点。近年来,许多研究都致力于阐明不同疾病和进展过程中循环微小 RNA(miRNA)的表达模式,这些模式可以作为 EOS 的诊断生物标志物。本研究的目的是分析选定 miRNA 的表达模式,并评估其对早期检测和治疗的诊断价值。
这是一项前瞻性的横断面研究,于 2021 年 7 月 1 日至 2022 年 6 月 30 日进行。我们在分娩后 24 小时内收集了败血症新生儿和非感染性新生儿的多余外周血和人口统计学数据,并通过文献筛选获得了 11 个候选 miRNA。首先,我们从选定新生儿的血清中提取候选 miRNA 并分析其表达水平,然后使用接收者操作特征(ROC)曲线选择差异表达的 miRNA。我们分析了它们的敏感性和特异性,并获得了最佳诊断面板。最后,通过差异表达的 miRNA,我们使用目标基因进行了基因本体(GO)富集和蛋白质-蛋白质相互作用(PPI)分析。
在 EOS 患者中,血清中的三种 miRNA(miR-223-3p、miR-15a-5p 和 miR-17-5p)明显下调,而 miR-146a-5p、miR-1-3p 和 miR-16-5p 上调。这些 miRNA 的诊断价值(miR-15a-5p,AUC = 0.67;miR-223-3p,AUC = 0.72;miR-16-5p,AUC = 0.68;miR-17-5p,AUC = 0.70;miR-1-3p,AUC = 0.69;miR-146a-5p,AUC = 0.72)中等,由 miR-15a-5p、miR-223-3p 和 miR-16-5p 构建的诊断面板具有较高的诊断价值(AUC = 0.85,敏感性:74.6%,特异性:86%),表明它们的联合应用可能是 EOS 临床诊断的有前途的生物标志物。根据 GO 富集分析,目标基因编码的大多数蛋白质位于细胞质中,作为细胞成分(CC),在分子功能(MF)中,大多数蛋白质作为蛋白结合的调节剂,在生物过程(BP)中。大多数基因在 RNA 聚合酶 II 启动子的转录中起正或负调节作用,通过 PPI 构建后,前 10 个枢纽基因是 CDKN1A、YAP1、CCNE1、CCND1、CCK6、ERBB4、CHEK1、DICER1、VEGFA 和 APP,按等级排序。
三 miRNA 面板(miR-15a-5p、miR-223-3p 和 miR-16-5p)可能是 EOS 筛查的新型非侵入性生物标志物。